Search Results For:
- Search results for:
- CEPI
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
2021
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
GHIAA2019\MapguideSearch Object
(
[search_parameters] => Array
(
[qs] => CEPI
)
[filters] => Array
(
[text_search] => CEPI
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[post__in] => Array
(
[0] => 8491
[1] => 8490
[2] => 8489
[3] => 8488
[4] => 8487
[5] => 8486
[6] => 8485
[7] => 8484
[8] => 8482
[9] => 8481
[10] => 8480
[11] => 8479
[12] => 8469
[13] => 8468
[14] => 8467
[15] => 8462
[16] => 8461
[17] => 8314
[18] => 8313
[19] => 8312
[20] => 8311
[21] => 8192
[22] => 8191
[23] => 8190
[24] => 8157
[25] => 8152
[26] => 8151
[27] => 8150
[28] => 8143
[29] => 8142
[30] => 8131
[31] => 8130
[32] => 8129
[33] => 8051
[34] => 5782
[35] => 5653
[36] => 5652
[37] => 5427
[38] => 4580
[39] => 4205
[40] => 4204
[41] => 4201
[42] => 4200
[43] => 4141
[44] => 4140
[45] => 4139
[46] => 4138
[47] => 4137
[48] => 4136
[49] => 4135
[50] => 4134
[51] => 4133
[52] => 4131
[53] => 4130
[54] => 4129
[55] => 4128
[56] => 3757
[57] => 3756
[58] => 3755
[59] => 3754
[60] => 3753
[61] => 3751
[62] => 3749
[63] => 3748
[64] => 3747
[65] => 3746
[66] => 3744
[67] => 3743
[68] => 3736
[69] => 3726
[70] => 3725
[71] => 3724
[72] => 3722
[73] => 3493
[74] => 3344
[75] => 3343
[76] => 3342
[77] => 3341
[78] => 3339
[79] => 3338
[80] => 3336
[81] => 3331
[82] => 3329
[83] => 3327
[84] => 3326
[85] => 3323
[86] => 3321
[87] => 3318
[88] => 3316
[89] => 3315
[90] => 2909
[91] => 2908
[92] => 2907
[93] => 2893
[94] => 2892
[95] => 2890
[96] => 2889
[97] => 2885
[98] => 1221
[99] => 1205
[100] => 1204
[101] => 1203
[102] => 1202
[103] => 1159
[104] => 996
[105] => 8491
[106] => 8490
[107] => 8489
[108] => 8488
[109] => 8487
[110] => 8486
[111] => 8485
[112] => 8484
[113] => 8482
[114] => 8481
[115] => 8480
[116] => 8479
[117] => 8469
[118] => 8468
[119] => 8467
[120] => 8462
[121] => 8461
[122] => 8314
[123] => 8313
[124] => 8312
[125] => 8311
[126] => 8192
[127] => 8191
[128] => 8190
[129] => 8157
[130] => 8152
[131] => 8151
[132] => 8150
[133] => 8143
[134] => 8142
[135] => 8131
[136] => 8130
[137] => 8129
[138] => 8051
[139] => 5782
[140] => 5653
[141] => 5652
[142] => 5427
[143] => 4580
[144] => 4205
[145] => 4204
[146] => 4201
[147] => 4200
[148] => 4141
[149] => 4140
[150] => 4139
[151] => 4138
[152] => 4137
[153] => 4136
[154] => 4135
[155] => 4134
[156] => 4133
[157] => 4131
[158] => 4130
[159] => 4129
[160] => 4128
[161] => 3757
[162] => 3756
[163] => 3755
[164] => 3754
[165] => 3753
[166] => 3751
[167] => 3749
[168] => 3748
[169] => 3747
[170] => 3746
[171] => 3744
[172] => 3743
[173] => 3736
[174] => 3726
[175] => 3725
[176] => 3724
[177] => 3722
[178] => 3493
[179] => 3344
[180] => 3343
[181] => 3342
[182] => 3341
[183] => 3339
[184] => 3338
[185] => 3336
[186] => 3331
[187] => 3329
[188] => 3327
[189] => 3326
[190] => 3323
[191] => 3321
[192] => 3318
[193] => 3316
[194] => 3315
[195] => 2909
[196] => 2908
[197] => 2907
[198] => 2893
[199] => 2892
[200] => 2890
[201] => 2889
[202] => 2885
[203] => 1221
[204] => 1205
[205] => 1204
[206] => 1203
[207] => 1202
[208] => 1159
[209] => 996
[210] => 5808
[211] => 4661
[212] => 4147
[213] => 4148
[214] => 4223
[215] => 4222
[216] => 4221
[217] => 4220
[218] => 4219
[219] => 4218
[220] => 4217
[221] => 4216
[222] => 4215
[223] => 4214
[224] => 4213
[225] => 4212
[226] => 4210
[227] => 4209
[228] => 4161
[229] => 4159
[230] => 4158
[231] => 4157
[232] => 4156
[233] => 4155
[234] => 4154
[235] => 4153
[236] => 4152
[237] => 4151
[238] => 4150
[239] => 4149
[240] => 4146
[241] => 3812
[242] => 3810
[243] => 3809
[244] => 3808
[245] => 3807
[246] => 3806
[247] => 3805
[248] => 3804
[249] => 3803
[250] => 3802
[251] => 3801
[252] => 3800
[253] => 3799
[254] => 3798
[255] => 3797
[256] => 3796
)
)
[text_agreement_args] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => CEPI
)
[text_provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => CEPI
)
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] =>
[text_agreement_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => CEPI
)
[query_vars] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => CEPI
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[orderby] => title
[order] => ASC
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[search_terms_count] => 1
[search_terms] => Array
(
[0] => CEPI
)
[search_orderby_title] => Array
(
[0] => wpry_posts.post_title LIKE '{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}CEPI{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}'
)
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT DISTINCT wpry_posts.*
FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) )
WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) ) OR ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) ) ) AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
ORDER BY wpry_posts.post_title ASC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 3313
[post_author] => 6
[post_date] => 2021-06-30 10:12:41
[post_date_gmt] => 2021-06-30 10:12:41
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 11:58:03
[post_modified_gmt] => 2021-09-15 11:58:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3313
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4126
[post_author] => 5
[post_date] => 2022-01-28 13:33:11
[post_date_gmt] => 2022-01-28 13:33:11
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:33:11
[post_modified_gmt] => 2022-01-28 13:33:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4126
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2882
[post_author] => 6
[post_date] => 2021-05-14 14:03:29
[post_date_gmt] => 2021-05-14 14:03:29
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 11:58:31
[post_modified_gmt] => 2021-09-15 11:58:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2882
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3719
[post_author] => 5
[post_date] => 2021-08-23 11:02:40
[post_date_gmt] => 2021-08-23 11:02:40
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 11:58:51
[post_modified_gmt] => 2021-09-15 11:58:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3719
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 8049
[post_author] => 5
[post_date] => 2022-12-12 08:37:47
[post_date_gmt] => 2022-12-12 08:37:47
[post_content] =>
[post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-12 08:37:47
[post_modified_gmt] => 2022-12-12 08:37:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=8049
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 994
[post_author] => 7
[post_date] => 2020-05-18 19:52:27
[post_date_gmt] => 2020-05-18 19:52:27
[post_content] =>
[post_title] => CEPI CfP3i Vaccine Funding Agreement Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 11:59:18
[post_modified_gmt] => 2021-09-15 11:59:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=994
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 6
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 3313
[post_author] => 6
[post_date] => 2021-06-30 10:12:41
[post_date_gmt] => 2021-06-30 10:12:41
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 11:58:03
[post_modified_gmt] => 2021-09-15 11:58:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3313
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 6
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] => 1
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => b07b72d0f5293e8069c8a04c212072a7
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] => Array
(
[0] => about
[1] => an
[2] => are
[3] => as
[4] => at
[5] => be
[6] => by
[7] => com
[8] => for
[9] => from
[10] => how
[11] => in
[12] => is
[13] => it
[14] => of
[15] => on
[16] => or
[17] => that
[18] => the
[19] => this
[20] => to
[21] => was
[22] => what
[23] => when
[24] => where
[25] => who
[26] => will
[27] => with
[28] => www
)
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => CEPI
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => CEPI
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[search_terms_count] => 1
[search_terms] => Array
(
[0] => CEPI
)
[search_orderby_title] => Array
(
[0] => wpry_posts.post_title LIKE '{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}CEPI{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}'
)
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT DISTINCT wpry_posts.*
FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) )
WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) ) OR ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) ) ) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
ORDER BY wpry_posts.post_title LIKE '{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}CEPI{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}' DESC, wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 8491
[post_author] => 5
[post_date] => 2023-01-19 11:34:54
[post_date_gmt] => 2023-01-19 11:34:54
[post_content] =>
[post_title] => CEPI CfP3i Vaccine Funding Agreement Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-vaccine-funding-agreement-template
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 11:34:54
[post_modified_gmt] => 2023-01-19 11:34:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8491
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 8490
[post_author] => 5
[post_date] => 2023-01-19 11:11:46
[post_date_gmt] => 2023-01-19 11:11:46
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 11:11:46
[post_modified_gmt] => 2023-01-19 11:11:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8490
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 8489
[post_author] => 5
[post_date] => 2023-01-19 10:44:52
[post_date_gmt] => 2023-01-19 10:44:52
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 10:44:52
[post_modified_gmt] => 2023-01-19 10:44:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8489
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 8488
[post_author] => 5
[post_date] => 2023-01-19 10:15:15
[post_date_gmt] => 2023-01-19 10:15:15
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 10:15:15
[post_modified_gmt] => 2023-01-19 10:15:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8488
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 8487
[post_author] => 5
[post_date] => 2023-01-19 09:59:54
[post_date_gmt] => 2023-01-19 09:59:54
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:59:54
[post_modified_gmt] => 2023-01-19 09:59:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8487
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 8486
[post_author] => 5
[post_date] => 2023-01-19 09:46:36
[post_date_gmt] => 2023-01-19 09:46:36
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:46:36
[post_modified_gmt] => 2023-01-19 09:46:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8486
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 8485
[post_author] => 5
[post_date] => 2023-01-19 09:39:38
[post_date_gmt] => 2023-01-19 09:39:38
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:39:38
[post_modified_gmt] => 2023-01-19 09:39:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8485
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 8484
[post_author] => 5
[post_date] => 2023-01-19 09:17:50
[post_date_gmt] => 2023-01-19 09:17:50
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:17:50
[post_modified_gmt] => 2023-01-19 09:17:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8484
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 8482
[post_author] => 5
[post_date] => 2023-01-18 16:32:52
[post_date_gmt] => 2023-01-18 16:32:52
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-18 16:32:52
[post_modified_gmt] => 2023-01-18 16:32:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8482
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 8481
[post_author] => 5
[post_date] => 2023-01-18 15:49:38
[post_date_gmt] => 2023-01-18 15:49:38
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 12:07:24
[post_modified_gmt] => 2023-01-19 12:07:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8481
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 8480
[post_author] => 5
[post_date] => 2023-01-17 17:53:00
[post_date_gmt] => 2023-01-17 17:53:00
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:53:00
[post_modified_gmt] => 2023-01-17 17:53:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8480
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 8479
[post_author] => 5
[post_date] => 2023-01-17 17:35:45
[post_date_gmt] => 2023-01-17 17:35:45
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:35:45
[post_modified_gmt] => 2023-01-17 17:35:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8479
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 8469
[post_author] => 5
[post_date] => 2023-01-13 13:35:47
[post_date_gmt] => 2023-01-13 13:35:47
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-13 13:35:47
[post_modified_gmt] => 2023-01-13 13:35:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8469
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 8468
[post_author] => 5
[post_date] => 2023-01-11 14:35:38
[post_date_gmt] => 2023-01-11 14:35:38
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 14:54:13
[post_modified_gmt] => 2023-01-11 14:54:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8468
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 8467
[post_author] => 5
[post_date] => 2023-01-11 14:29:13
[post_date_gmt] => 2023-01-11 14:29:13
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 14:36:41
[post_modified_gmt] => 2023-01-11 14:36:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8467
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 8462
[post_author] => 5
[post_date] => 2023-01-10 12:12:52
[post_date_gmt] => 2023-01-10 12:12:52
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 12:21:16
[post_modified_gmt] => 2023-01-10 12:21:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8462
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 8461
[post_author] => 5
[post_date] => 2023-01-10 09:08:41
[post_date_gmt] => 2023-01-10 09:08:41
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 09:17:07
[post_modified_gmt] => 2023-01-10 09:17:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8461
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 8314
[post_author] => 5
[post_date] => 2022-12-13 11:46:36
[post_date_gmt] => 2022-12-13 11:46:36
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 11:46:36
[post_modified_gmt] => 2022-12-13 11:46:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8314
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 8313
[post_author] => 5
[post_date] => 2022-12-13 10:48:56
[post_date_gmt] => 2022-12-13 10:48:56
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 10:48:56
[post_modified_gmt] => 2022-12-13 10:48:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8313
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 8312
[post_author] => 5
[post_date] => 2022-12-13 10:35:08
[post_date_gmt] => 2022-12-13 10:35:08
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 10:35:08
[post_modified_gmt] => 2022-12-13 10:35:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8312
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 8311
[post_author] => 5
[post_date] => 2022-12-13 10:09:44
[post_date_gmt] => 2022-12-13 10:09:44
[post_content] =>
[post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 10:09:44
[post_modified_gmt] => 2022-12-13 10:09:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8311
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 8192
[post_author] => 5
[post_date] => 2022-12-13 09:04:26
[post_date_gmt] => 2022-12-13 09:04:26
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 09:05:52
[post_modified_gmt] => 2022-12-13 09:05:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8192
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 8191
[post_author] => 5
[post_date] => 2022-12-12 16:19:19
[post_date_gmt] => 2022-12-12 16:19:19
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:55:07
[post_modified_gmt] => 2022-12-13 12:55:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8191
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 8190
[post_author] => 5
[post_date] => 2022-12-12 15:29:46
[post_date_gmt] => 2022-12-12 15:29:46
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-14 13:05:30
[post_modified_gmt] => 2022-12-14 13:05:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8190
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 8157
[post_author] => 5
[post_date] => 2022-12-12 15:23:50
[post_date_gmt] => 2022-12-12 15:23:50
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-28 14:06:57
[post_modified_gmt] => 2023-03-28 14:06:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8157
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 8152
[post_author] => 5
[post_date] => 2022-12-12 12:04:21
[post_date_gmt] => 2022-12-12 12:04:21
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:56:37
[post_modified_gmt] => 2022-12-13 12:56:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8152
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 8151
[post_author] => 5
[post_date] => 2022-12-12 11:56:08
[post_date_gmt] => 2022-12-12 11:56:08
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 13:04:22
[post_modified_gmt] => 2022-12-13 13:04:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 8150
[post_author] => 5
[post_date] => 2022-12-12 11:21:26
[post_date_gmt] => 2022-12-12 11:21:26
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-12 11:48:09
[post_modified_gmt] => 2022-12-12 11:48:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 8143
[post_author] => 5
[post_date] => 2022-12-12 11:10:19
[post_date_gmt] => 2022-12-12 11:10:19
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-12 11:10:19
[post_modified_gmt] => 2022-12-12 11:10:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8143
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 8142
[post_author] => 5
[post_date] => 2022-12-12 10:40:31
[post_date_gmt] => 2022-12-12 10:40:31
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:57:50
[post_modified_gmt] => 2022-12-13 12:57:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8142
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 8131
[post_author] => 5
[post_date] => 2022-12-12 09:57:36
[post_date_gmt] => 2022-12-12 09:57:36
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:49:55
[post_modified_gmt] => 2022-12-13 12:49:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 8130
[post_author] => 5
[post_date] => 2022-12-12 09:34:49
[post_date_gmt] => 2022-12-12 09:34:49
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:51:49
[post_modified_gmt] => 2022-12-13 12:51:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 8129
[post_author] => 5
[post_date] => 2022-12-12 08:55:53
[post_date_gmt] => 2022-12-12 08:55:53
[post_content] =>
[post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:45:31
[post_modified_gmt] => 2022-12-13 12:45:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 8051
[post_author] => 5
[post_date] => 2022-12-12 08:39:19
[post_date_gmt] => 2022-12-12 08:39:19
[post_content] =>
[post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:54:45
[post_modified_gmt] => 2023-01-10 13:54:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8051
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 5782
[post_author] => 5
[post_date] => 2022-09-16 07:28:56
[post_date_gmt] => 2022-09-16 07:28:56
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:52:08
[post_modified_gmt] => 2023-01-10 13:52:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 5653
[post_author] => 5
[post_date] => 2022-08-25 12:56:30
[post_date_gmt] => 2022-08-25 12:56:30
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 12:24:08
[post_modified_gmt] => 2023-01-10 12:24:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5653
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 5652
[post_author] => 5
[post_date] => 2022-08-25 12:26:53
[post_date_gmt] => 2022-08-25 12:26:53
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:46:10
[post_modified_gmt] => 2023-01-10 11:46:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5652
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 5427
[post_author] => 5
[post_date] => 2022-07-22 15:20:29
[post_date_gmt] => 2022-07-22 15:20:29
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 13:37:17
[post_modified_gmt] => 2023-01-05 13:37:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5427
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 4580
[post_author] => 5
[post_date] => 2022-03-31 14:34:38
[post_date_gmt] => 2022-03-31 14:34:38
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:02:54
[post_modified_gmt] => 2023-01-05 14:02:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4580
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 4205
[post_author] => 5
[post_date] => 2022-02-28 15:24:19
[post_date_gmt] => 2022-02-28 15:24:19
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 12:59:13
[post_modified_gmt] => 2022-10-12 12:59:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 4204
[post_author] => 5
[post_date] => 2022-02-28 14:53:11
[post_date_gmt] => 2022-02-28 14:53:11
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-14 13:07:32
[post_modified_gmt] => 2022-12-14 13:07:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 4201
[post_author] => 5
[post_date] => 2022-02-28 13:33:22
[post_date_gmt] => 2022-02-28 13:33:22
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:13:57
[post_modified_gmt] => 2023-01-10 13:13:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 4200
[post_author] => 5
[post_date] => 2022-02-28 13:13:29
[post_date_gmt] => 2022-02-28 13:13:29
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 11:13:52
[post_modified_gmt] => 2022-10-12 11:13:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 4141
[post_author] => 5
[post_date] => 2022-01-31 14:31:23
[post_date_gmt] => 2022-01-31 14:31:23
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:40:20
[post_modified_gmt] => 2023-01-10 10:40:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 4140
[post_author] => 5
[post_date] => 2022-01-31 14:22:03
[post_date_gmt] => 2022-01-31 14:22:03
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:54:15
[post_modified_gmt] => 2023-01-10 10:54:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 4139
[post_author] => 5
[post_date] => 2022-01-31 14:18:32
[post_date_gmt] => 2022-01-31 14:18:32
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:58:00
[post_modified_gmt] => 2023-01-10 10:58:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 4138
[post_author] => 5
[post_date] => 2022-01-31 14:09:33
[post_date_gmt] => 2022-01-31 14:09:33
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:59:39
[post_modified_gmt] => 2023-01-10 10:59:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4138
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 4137
[post_author] => 5
[post_date] => 2022-01-31 13:53:37
[post_date_gmt] => 2022-01-31 13:53:37
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:02:20
[post_modified_gmt] => 2023-01-10 11:02:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 4136
[post_author] => 5
[post_date] => 2022-01-31 13:42:47
[post_date_gmt] => 2022-01-31 13:42:47
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:01:51
[post_modified_gmt] => 2023-01-10 11:01:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 4135
[post_author] => 5
[post_date] => 2022-01-31 13:25:08
[post_date_gmt] => 2022-01-31 13:25:08
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:59:11
[post_modified_gmt] => 2023-01-10 10:59:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 4134
[post_author] => 5
[post_date] => 2022-01-31 12:56:28
[post_date_gmt] => 2022-01-31 12:56:28
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:58:24
[post_modified_gmt] => 2023-01-10 10:58:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 4133
[post_author] => 5
[post_date] => 2022-01-31 12:22:56
[post_date_gmt] => 2022-01-31 12:22:56
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:56:11
[post_modified_gmt] => 2023-01-10 10:56:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4133
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 4131
[post_author] => 5
[post_date] => 2022-01-29 16:21:19
[post_date_gmt] => 2022-01-29 16:21:19
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:56:47
[post_modified_gmt] => 2023-01-10 10:56:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 4130
[post_author] => 5
[post_date] => 2022-01-29 15:34:50
[post_date_gmt] => 2022-01-29 15:34:50
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:57:20
[post_modified_gmt] => 2023-01-10 10:57:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 4129
[post_author] => 5
[post_date] => 2022-01-28 14:43:06
[post_date_gmt] => 2022-01-28 14:43:06
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:53:31
[post_modified_gmt] => 2023-01-10 10:53:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 4128
[post_author] => 5
[post_date] => 2022-01-28 13:38:44
[post_date_gmt] => 2022-01-28 13:38:44
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:07:15
[post_modified_gmt] => 2023-01-10 11:07:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 3757
[post_author] => 5
[post_date] => 2021-08-25 08:42:34
[post_date_gmt] => 2021-08-25 08:42:34
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:47:08
[post_modified_gmt] => 2023-01-11 15:47:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3757
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 3756
[post_author] => 5
[post_date] => 2021-08-25 08:10:37
[post_date_gmt] => 2021-08-25 08:10:37
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:39:31
[post_modified_gmt] => 2023-01-11 15:39:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3756
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 3755
[post_author] => 5
[post_date] => 2021-08-25 07:55:51
[post_date_gmt] => 2021-08-25 07:55:51
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:24:11
[post_modified_gmt] => 2023-01-19 09:24:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3755
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 3754
[post_author] => 5
[post_date] => 2021-08-24 13:43:37
[post_date_gmt] => 2021-08-24 13:43:37
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-12 13:59:38
[post_modified_gmt] => 2023-01-12 13:59:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3754
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 3753
[post_author] => 5
[post_date] => 2021-08-24 13:14:41
[post_date_gmt] => 2021-08-24 13:14:41
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 10:13:40
[post_modified_gmt] => 2023-01-19 10:13:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3753
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 3751
[post_author] => 5
[post_date] => 2021-08-24 12:54:56
[post_date_gmt] => 2021-08-24 12:54:56
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-12 13:20:29
[post_modified_gmt] => 2023-01-12 13:20:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3751
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 3749
[post_author] => 5
[post_date] => 2021-08-24 12:40:53
[post_date_gmt] => 2021-08-24 12:40:53
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-12 13:33:44
[post_modified_gmt] => 2023-01-12 13:33:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3749
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 3748
[post_author] => 5
[post_date] => 2021-08-24 12:31:07
[post_date_gmt] => 2021-08-24 12:31:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 14:17:38
[post_modified_gmt] => 2023-01-11 14:17:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 3747
[post_author] => 5
[post_date] => 2021-08-24 11:12:07
[post_date_gmt] => 2021-08-24 11:12:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:28:33
[post_modified_gmt] => 2023-01-11 15:28:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3747
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 3746
[post_author] => 5
[post_date] => 2021-08-24 10:45:05
[post_date_gmt] => 2021-08-24 10:45:05
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:55:51
[post_modified_gmt] => 2023-01-11 15:55:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3746
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 3744
[post_author] => 5
[post_date] => 2021-08-24 10:32:54
[post_date_gmt] => 2021-08-24 10:32:54
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-28 14:06:21
[post_modified_gmt] => 2023-03-28 14:06:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3744
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 3743
[post_author] => 5
[post_date] => 2021-08-24 10:19:00
[post_date_gmt] => 2021-08-24 10:19:00
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:53:13
[post_modified_gmt] => 2023-01-11 15:53:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3743
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 3736
[post_author] => 5
[post_date] => 2021-08-24 07:47:09
[post_date_gmt] => 2021-08-24 07:47:09
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-13 14:46:43
[post_modified_gmt] => 2023-01-13 14:46:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3736
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 3726
[post_author] => 5
[post_date] => 2021-08-23 16:13:39
[post_date_gmt] => 2021-08-23 16:13:39
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:23:48
[post_modified_gmt] => 2023-01-11 15:23:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3726
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 3725
[post_author] => 5
[post_date] => 2021-08-23 13:56:41
[post_date_gmt] => 2021-08-23 13:56:41
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:50:35
[post_modified_gmt] => 2023-01-11 15:50:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3725
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 3724
[post_author] => 5
[post_date] => 2021-08-23 13:11:07
[post_date_gmt] => 2021-08-23 13:11:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:27:12
[post_modified_gmt] => 2023-01-11 15:27:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3724
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 3722
[post_author] => 5
[post_date] => 2021-08-23 12:12:50
[post_date_gmt] => 2021-08-23 12:12:50
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:42:28
[post_modified_gmt] => 2023-01-11 15:42:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3722
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 3493
[post_author] => 5
[post_date] => 2021-08-10 11:15:39
[post_date_gmt] => 2021-08-10 11:15:39
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 14:19:31
[post_modified_gmt] => 2023-01-10 14:19:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3493
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 3344
[post_author] => 6
[post_date] => 2021-06-30 13:02:36
[post_date_gmt] => 2021-06-30 13:02:36
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-22
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 15:29:20
[post_modified_gmt] => 2023-01-05 15:29:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3344
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 3343
[post_author] => 6
[post_date] => 2021-06-30 12:57:07
[post_date_gmt] => 2021-06-30 12:57:07
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-21
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 15:31:21
[post_modified_gmt] => 2023-01-05 15:31:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3343
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 3342
[post_author] => 6
[post_date] => 2021-06-30 12:50:17
[post_date_gmt] => 2021-06-30 12:50:17
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 15:05:20
[post_modified_gmt] => 2023-01-05 15:05:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3342
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 3341
[post_author] => 6
[post_date] => 2021-06-30 12:44:43
[post_date_gmt] => 2021-06-30 12:44:43
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 15:04:39
[post_modified_gmt] => 2023-01-05 15:04:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3341
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 3339
[post_author] => 6
[post_date] => 2021-06-30 12:37:28
[post_date_gmt] => 2021-06-30 12:37:28
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-12 13:27:08
[post_modified_gmt] => 2023-01-12 13:27:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3339
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 3338
[post_author] => 6
[post_date] => 2021-06-30 12:27:08
[post_date_gmt] => 2021-06-30 12:27:08
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:23:29
[post_modified_gmt] => 2023-01-05 14:23:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3338
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 3336
[post_author] => 6
[post_date] => 2021-06-30 12:18:57
[post_date_gmt] => 2021-06-30 12:18:57
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:57:18
[post_modified_gmt] => 2023-01-05 14:57:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3336
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 3331
[post_author] => 6
[post_date] => 2021-06-30 12:09:31
[post_date_gmt] => 2021-06-30 12:09:31
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:55:43
[post_modified_gmt] => 2023-01-05 14:55:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3331
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 3329
[post_author] => 6
[post_date] => 2021-06-30 12:04:02
[post_date_gmt] => 2021-06-30 12:04:02
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-09 13:18:35
[post_modified_gmt] => 2023-01-09 13:18:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3329
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 3327
[post_author] => 6
[post_date] => 2021-06-30 11:47:34
[post_date_gmt] => 2021-06-30 11:47:34
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 13:58:59
[post_modified_gmt] => 2023-01-05 13:58:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3327
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 3326
[post_author] => 6
[post_date] => 2021-06-30 11:35:26
[post_date_gmt] => 2021-06-30 11:35:26
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-28 14:05:33
[post_modified_gmt] => 2023-03-28 14:05:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3326
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 3323
[post_author] => 6
[post_date] => 2021-06-30 11:15:16
[post_date_gmt] => 2021-06-30 11:15:16
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-09 13:12:53
[post_modified_gmt] => 2023-01-09 13:12:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3323
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 3321
[post_author] => 6
[post_date] => 2021-06-30 11:12:36
[post_date_gmt] => 2021-06-30 11:12:36
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-13-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:03:32
[post_modified_gmt] => 2023-01-05 14:03:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3321
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 3318
[post_author] => 6
[post_date] => 2021-06-30 10:46:25
[post_date_gmt] => 2021-06-30 10:46:25
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 09:20:27
[post_modified_gmt] => 2023-01-10 09:20:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3318
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 3316
[post_author] => 6
[post_date] => 2021-06-30 10:25:45
[post_date_gmt] => 2021-06-30 10:25:45
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-09 12:51:00
[post_modified_gmt] => 2023-01-09 12:51:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3316
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 3315
[post_author] => 6
[post_date] => 2021-06-30 10:19:01
[post_date_gmt] => 2021-06-30 10:19:01
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:19:23
[post_modified_gmt] => 2023-01-05 14:19:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3315
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 2909
[post_author] => 6
[post_date] => 2021-05-19 15:13:58
[post_date_gmt] => 2021-05-19 15:13:58
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:42:59
[post_modified_gmt] => 2023-01-10 13:42:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 2908
[post_author] => 6
[post_date] => 2021-05-19 15:08:05
[post_date_gmt] => 2021-05-19 15:08:05
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:40:09
[post_modified_gmt] => 2023-01-10 13:40:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 2907
[post_author] => 6
[post_date] => 2021-05-19 14:46:20
[post_date_gmt] => 2021-05-19 14:46:20
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 15:03:09
[post_modified_gmt] => 2022-08-12 15:03:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2907
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 2893
[post_author] => 6
[post_date] => 2021-05-19 14:40:45
[post_date_gmt] => 2021-05-19 14:40:45
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-28 14:17:46
[post_modified_gmt] => 2023-03-28 14:17:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 14:00:44
[post_modified_gmt] => 2023-01-10 14:00:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:14:51
[post_modified_gmt] => 2023-01-10 11:14:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 12:43:57
[post_modified_gmt] => 2023-01-10 12:43:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 2885
[post_author] => 5
[post_date] => 2021-05-14 18:17:37
[post_date_gmt] => 2021-05-14 18:17:37
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:16:30
[post_modified_gmt] => 2023-01-10 13:16:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2885
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 1221
[post_author] => 6
[post_date] => 2020-05-22 20:09:53
[post_date_gmt] => 2020-05-22 20:09:53
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfpi3-template-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:12:53
[post_modified_gmt] => 2023-01-17 17:12:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 1205
[post_author] => 6
[post_date] => 2020-05-22 19:33:17
[post_date_gmt] => 2020-05-22 19:33:17
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 12:05:50
[post_modified_gmt] => 2023-01-19 12:05:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 1204
[post_author] => 6
[post_date] => 2020-05-22 19:31:46
[post_date_gmt] => 2020-05-22 19:31:46
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:26:09
[post_modified_gmt] => 2023-01-19 09:26:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 1203
[post_author] => 6
[post_date] => 2020-05-22 19:30:52
[post_date_gmt] => 2020-05-22 19:30:52
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-13 14:49:22
[post_modified_gmt] => 2023-01-13 14:49:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 1202
[post_author] => 6
[post_date] => 2020-05-22 19:28:49
[post_date_gmt] => 2020-05-22 19:28:49
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-13 14:47:56
[post_modified_gmt] => 2023-01-13 14:47:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 1159
[post_author] => 6
[post_date] => 2020-05-21 23:14:15
[post_date_gmt] => 2020-05-21 23:14:15
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:13:30
[post_modified_gmt] => 2023-01-17 17:13:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 996
[post_author] => 7
[post_date] => 2020-05-18 19:58:18
[post_date_gmt] => 2020-05-18 19:58:18
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:16:23
[post_modified_gmt] => 2023-01-17 17:16:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 5808
[post_author] => 5
[post_date] => 2022-10-04 10:04:03
[post_date_gmt] => 2022-10-04 10:04:03
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-04 10:04:03
[post_modified_gmt] => 2022-10-04 10:04:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 4661
[post_author] => 5
[post_date] => 2022-04-20 08:13:06
[post_date_gmt] => 2022-04-20 08:13:06
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:53:17
[post_modified_gmt] => 2022-10-03 13:53:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4661
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 4147
[post_author] => 5
[post_date] => 2022-04-18 12:53:51
[post_date_gmt] => 2022-04-18 12:53:51
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 16:24:43
[post_modified_gmt] => 2022-12-15 16:24:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 4148
[post_author] => 5
[post_date] => 2022-04-12 08:59:45
[post_date_gmt] => 2022-04-12 08:59:45
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-04 09:32:39
[post_modified_gmt] => 2022-10-04 09:32:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4148
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 4223
[post_author] => 5
[post_date] => 2022-03-04 09:43:58
[post_date_gmt] => 2022-03-04 09:43:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 18:00:18
[post_modified_gmt] => 2022-05-31 18:00:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4223
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 4222
[post_author] => 5
[post_date] => 2022-03-04 09:14:41
[post_date_gmt] => 2022-03-04 09:14:41
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 11:13:06
[post_modified_gmt] => 2022-10-12 11:13:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4222
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 4221
[post_author] => 5
[post_date] => 2022-03-04 09:05:29
[post_date_gmt] => 2022-03-04 09:05:29
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:36:15
[post_modified_gmt] => 2022-09-26 14:36:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 4220
[post_author] => 5
[post_date] => 2022-03-04 08:47:04
[post_date_gmt] => 2022-03-04 08:47:04
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:08:10
[post_modified_gmt] => 2022-05-31 15:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 4219
[post_author] => 5
[post_date] => 2022-03-04 08:02:15
[post_date_gmt] => 2022-03-04 08:02:15
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-04 15:55:41
[post_modified_gmt] => 2023-01-04 15:55:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 4218
[post_author] => 5
[post_date] => 2022-03-03 14:17:53
[post_date_gmt] => 2022-03-03 14:17:53
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-04 15:10:14
[post_modified_gmt] => 2023-01-04 15:10:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 4217
[post_author] => 5
[post_date] => 2022-03-03 13:59:58
[post_date_gmt] => 2022-03-03 13:59:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:56:43
[post_modified_gmt] => 2022-05-31 17:56:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 4216
[post_author] => 5
[post_date] => 2022-03-03 13:45:21
[post_date_gmt] => 2022-03-03 13:45:21
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:56:00
[post_modified_gmt] => 2022-05-31 17:56:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 4215
[post_author] => 5
[post_date] => 2022-03-03 13:31:56
[post_date_gmt] => 2022-03-03 13:31:56
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 10:41:55
[post_modified_gmt] => 2022-09-29 10:41:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 4214
[post_author] => 5
[post_date] => 2022-03-03 12:54:33
[post_date_gmt] => 2022-03-03 12:54:33
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 16:33:50
[post_modified_gmt] => 2022-12-15 16:33:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 4213
[post_author] => 5
[post_date] => 2022-03-03 10:54:01
[post_date_gmt] => 2022-03-03 10:54:01
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:05:32
[post_modified_gmt] => 2022-05-31 15:05:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4213
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 4212
[post_author] => 5
[post_date] => 2022-03-02 14:54:16
[post_date_gmt] => 2022-03-02 14:54:16
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 12:56:25
[post_modified_gmt] => 2022-10-12 12:56:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4212
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 4210
[post_author] => 5
[post_date] => 2022-03-02 13:14:31
[post_date_gmt] => 2022-03-02 13:14:31
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:03:49
[post_modified_gmt] => 2022-07-13 12:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4210
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 4209
[post_author] => 5
[post_date] => 2022-03-02 12:07:13
[post_date_gmt] => 2022-03-02 12:07:13
[post_content] =>
[post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-13 13:16:54
[post_modified_gmt] => 2022-10-13 13:16:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4209
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 4161
[post_author] => 5
[post_date] => 2022-02-02 13:48:58
[post_date_gmt] => 2022-02-02 13:48:58
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:53:28
[post_modified_gmt] => 2022-12-15 09:53:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4161
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 4159
[post_author] => 5
[post_date] => 2022-02-02 13:10:48
[post_date_gmt] => 2022-02-02 13:10:48
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 11:15:11
[post_modified_gmt] => 2022-10-12 11:15:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 4158
[post_author] => 5
[post_date] => 2022-02-02 13:00:08
[post_date_gmt] => 2022-02-02 13:00:08
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-03 12:48:45
[post_modified_gmt] => 2023-01-03 12:48:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 4157
[post_author] => 5
[post_date] => 2022-02-02 12:54:56
[post_date_gmt] => 2022-02-02 12:54:56
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:13:37
[post_modified_gmt] => 2022-04-18 13:13:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4157
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 4156
[post_author] => 5
[post_date] => 2022-02-02 12:36:42
[post_date_gmt] => 2022-02-02 12:36:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-04 15:10:37
[post_modified_gmt] => 2023-01-04 15:10:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 4155
[post_author] => 5
[post_date] => 2022-02-02 12:19:16
[post_date_gmt] => 2022-02-02 12:19:16
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:26
[post_modified_gmt] => 2022-04-18 13:12:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 4154
[post_author] => 5
[post_date] => 2022-02-02 12:13:41
[post_date_gmt] => 2022-02-02 12:13:41
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-02 12:13:41
[post_modified_gmt] => 2022-02-02 12:13:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4154
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 4153
[post_author] => 5
[post_date] => 2022-02-02 12:10:13
[post_date_gmt] => 2022-02-02 12:10:13
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:28:28
[post_modified_gmt] => 2022-09-29 11:28:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4153
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 4152
[post_author] => 5
[post_date] => 2022-02-02 11:51:54
[post_date_gmt] => 2022-02-02 11:51:54
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:57:07
[post_modified_gmt] => 2022-09-26 14:57:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4152
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 4151
[post_author] => 5
[post_date] => 2022-02-02 11:39:24
[post_date_gmt] => 2022-02-02 11:39:24
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 13:00:22
[post_modified_gmt] => 2022-10-12 13:00:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 4150
[post_author] => 5
[post_date] => 2022-02-02 10:24:30
[post_date_gmt] => 2022-02-02 10:24:30
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:03
[post_modified_gmt] => 2022-04-18 13:01:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 4149
[post_author] => 5
[post_date] => 2022-02-02 10:15:42
[post_date_gmt] => 2022-02-02 10:15:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 16:35:19
[post_modified_gmt] => 2022-12-15 16:35:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4149
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 4146
[post_author] => 5
[post_date] => 2022-02-02 07:28:42
[post_date_gmt] => 2022-02-02 07:28:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-13 13:18:01
[post_modified_gmt] => 2022-10-13 13:18:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4146
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 3812
[post_author] => 5
[post_date] => 2021-09-10 12:44:57
[post_date_gmt] => 2021-09-10 12:44:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:53:37
[post_modified_gmt] => 2022-10-03 13:53:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3812
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 3810
[post_author] => 5
[post_date] => 2021-09-10 12:21:33
[post_date_gmt] => 2021-09-10 12:21:33
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 11:25:05
[post_modified_gmt] => 2022-10-12 11:25:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3810
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 3809
[post_author] => 5
[post_date] => 2021-09-10 12:11:12
[post_date_gmt] => 2021-09-10 12:11:12
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:54:22
[post_modified_gmt] => 2022-10-03 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 3808
[post_author] => 5
[post_date] => 2021-09-10 11:59:11
[post_date_gmt] => 2021-09-10 11:59:11
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-16 08:32:00
[post_modified_gmt] => 2022-12-16 08:32:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 3807
[post_author] => 5
[post_date] => 2021-09-10 11:55:25
[post_date_gmt] => 2021-09-10 11:55:25
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 15:01:53
[post_modified_gmt] => 2022-12-15 15:01:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[141] => WP_Post Object
(
[ID] => 3806
[post_author] => 5
[post_date] => 2021-09-10 11:47:18
[post_date_gmt] => 2021-09-10 11:47:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:55:26
[post_modified_gmt] => 2022-10-03 13:55:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[142] => WP_Post Object
(
[ID] => 3805
[post_author] => 5
[post_date] => 2021-09-10 11:33:53
[post_date_gmt] => 2021-09-10 11:33:53
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-03 13:02:35
[post_modified_gmt] => 2023-01-03 13:02:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[143] => WP_Post Object
(
[ID] => 3804
[post_author] => 5
[post_date] => 2021-09-10 11:20:59
[post_date_gmt] => 2021-09-10 11:20:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-21 12:59:30
[post_modified_gmt] => 2023-03-21 12:59:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[144] => WP_Post Object
(
[ID] => 3803
[post_author] => 5
[post_date] => 2021-09-10 10:54:42
[post_date_gmt] => 2021-09-10 10:54:42
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:57:32
[post_modified_gmt] => 2022-10-03 13:57:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3803
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[145] => WP_Post Object
(
[ID] => 3802
[post_author] => 5
[post_date] => 2021-09-10 10:45:57
[post_date_gmt] => 2021-09-10 10:45:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:58:08
[post_modified_gmt] => 2022-10-03 13:58:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[146] => WP_Post Object
(
[ID] => 3801
[post_author] => 5
[post_date] => 2021-09-10 10:36:30
[post_date_gmt] => 2021-09-10 10:36:30
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-14 15:47:05
[post_modified_gmt] => 2022-12-14 15:47:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[147] => WP_Post Object
(
[ID] => 3800
[post_author] => 5
[post_date] => 2021-09-10 10:25:59
[post_date_gmt] => 2021-09-10 10:25:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:58:45
[post_modified_gmt] => 2022-10-03 13:58:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[148] => WP_Post Object
(
[ID] => 3799
[post_author] => 5
[post_date] => 2021-09-10 10:07:18
[post_date_gmt] => 2021-09-10 10:07:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-16 12:45:40
[post_modified_gmt] => 2022-12-16 12:45:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3799
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[149] => WP_Post Object
(
[ID] => 3798
[post_author] => 5
[post_date] => 2021-09-10 10:02:07
[post_date_gmt] => 2021-09-10 10:02:07
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:59:19
[post_modified_gmt] => 2022-10-03 13:59:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[150] => WP_Post Object
(
[ID] => 3797
[post_author] => 5
[post_date] => 2021-09-10 09:54:44
[post_date_gmt] => 2021-09-10 09:54:44
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:59:36
[post_modified_gmt] => 2022-10-03 13:59:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[151] => WP_Post Object
(
[ID] => 3796
[post_author] => 5
[post_date] => 2021-09-10 09:03:43
[post_date_gmt] => 2021-09-10 09:03:43
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-11-09 15:00:19
[post_modified_gmt] => 2022-11-09 15:00:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 152
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 8491
[post_author] => 5
[post_date] => 2023-01-19 11:34:54
[post_date_gmt] => 2023-01-19 11:34:54
[post_content] =>
[post_title] => CEPI CfP3i Vaccine Funding Agreement Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-vaccine-funding-agreement-template
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 11:34:54
[post_modified_gmt] => 2023-01-19 11:34:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8491
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 152
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] => 1
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => d1a97f870fa3d3de84ebbf4dd1ae72e2
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] => Array
(
[0] => about
[1] => an
[2] => are
[3] => as
[4] => at
[5] => be
[6] => by
[7] => com
[8] => for
[9] => from
[10] => how
[11] => in
[12] => is
[13] => it
[14] => of
[15] => on
[16] => or
[17] => that
[18] => the
[19] => this
[20] => to
[21] => was
[22] => what
[23] => when
[24] => where
[25] => who
[26] => will
[27] => with
[28] => www
)
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 8491
[post_author] => 5
[post_date] => 2023-01-19 11:34:54
[post_date_gmt] => 2023-01-19 11:34:54
[post_content] =>
[post_title] => CEPI CfP3i Vaccine Funding Agreement Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-vaccine-funding-agreement-template
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 11:34:54
[post_modified_gmt] => 2023-01-19 11:34:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8491
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 8490
[post_author] => 5
[post_date] => 2023-01-19 11:11:46
[post_date_gmt] => 2023-01-19 11:11:46
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 11:11:46
[post_modified_gmt] => 2023-01-19 11:11:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8490
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 8489
[post_author] => 5
[post_date] => 2023-01-19 10:44:52
[post_date_gmt] => 2023-01-19 10:44:52
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 10:44:52
[post_modified_gmt] => 2023-01-19 10:44:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8489
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 8488
[post_author] => 5
[post_date] => 2023-01-19 10:15:15
[post_date_gmt] => 2023-01-19 10:15:15
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 10:15:15
[post_modified_gmt] => 2023-01-19 10:15:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8488
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 8487
[post_author] => 5
[post_date] => 2023-01-19 09:59:54
[post_date_gmt] => 2023-01-19 09:59:54
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:59:54
[post_modified_gmt] => 2023-01-19 09:59:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8487
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 8486
[post_author] => 5
[post_date] => 2023-01-19 09:46:36
[post_date_gmt] => 2023-01-19 09:46:36
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:46:36
[post_modified_gmt] => 2023-01-19 09:46:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8486
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 8485
[post_author] => 5
[post_date] => 2023-01-19 09:39:38
[post_date_gmt] => 2023-01-19 09:39:38
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:39:38
[post_modified_gmt] => 2023-01-19 09:39:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8485
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 8484
[post_author] => 5
[post_date] => 2023-01-19 09:17:50
[post_date_gmt] => 2023-01-19 09:17:50
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:17:50
[post_modified_gmt] => 2023-01-19 09:17:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8484
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 8482
[post_author] => 5
[post_date] => 2023-01-18 16:32:52
[post_date_gmt] => 2023-01-18 16:32:52
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-18 16:32:52
[post_modified_gmt] => 2023-01-18 16:32:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8482
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 8481
[post_author] => 5
[post_date] => 2023-01-18 15:49:38
[post_date_gmt] => 2023-01-18 15:49:38
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 12:07:24
[post_modified_gmt] => 2023-01-19 12:07:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8481
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 8480
[post_author] => 5
[post_date] => 2023-01-17 17:53:00
[post_date_gmt] => 2023-01-17 17:53:00
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:53:00
[post_modified_gmt] => 2023-01-17 17:53:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8480
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 8479
[post_author] => 5
[post_date] => 2023-01-17 17:35:45
[post_date_gmt] => 2023-01-17 17:35:45
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:35:45
[post_modified_gmt] => 2023-01-17 17:35:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8479
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 8469
[post_author] => 5
[post_date] => 2023-01-13 13:35:47
[post_date_gmt] => 2023-01-13 13:35:47
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-13 13:35:47
[post_modified_gmt] => 2023-01-13 13:35:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8469
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 8468
[post_author] => 5
[post_date] => 2023-01-11 14:35:38
[post_date_gmt] => 2023-01-11 14:35:38
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 14:54:13
[post_modified_gmt] => 2023-01-11 14:54:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8468
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 8467
[post_author] => 5
[post_date] => 2023-01-11 14:29:13
[post_date_gmt] => 2023-01-11 14:29:13
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 14:36:41
[post_modified_gmt] => 2023-01-11 14:36:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8467
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 8462
[post_author] => 5
[post_date] => 2023-01-10 12:12:52
[post_date_gmt] => 2023-01-10 12:12:52
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 12:21:16
[post_modified_gmt] => 2023-01-10 12:21:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8462
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 8461
[post_author] => 5
[post_date] => 2023-01-10 09:08:41
[post_date_gmt] => 2023-01-10 09:08:41
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 09:17:07
[post_modified_gmt] => 2023-01-10 09:17:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8461
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 8314
[post_author] => 5
[post_date] => 2022-12-13 11:46:36
[post_date_gmt] => 2022-12-13 11:46:36
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 11:46:36
[post_modified_gmt] => 2022-12-13 11:46:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8314
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 8313
[post_author] => 5
[post_date] => 2022-12-13 10:48:56
[post_date_gmt] => 2022-12-13 10:48:56
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 10:48:56
[post_modified_gmt] => 2022-12-13 10:48:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8313
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 8312
[post_author] => 5
[post_date] => 2022-12-13 10:35:08
[post_date_gmt] => 2022-12-13 10:35:08
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 10:35:08
[post_modified_gmt] => 2022-12-13 10:35:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8312
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 8311
[post_author] => 5
[post_date] => 2022-12-13 10:09:44
[post_date_gmt] => 2022-12-13 10:09:44
[post_content] =>
[post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 10:09:44
[post_modified_gmt] => 2022-12-13 10:09:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8311
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 8192
[post_author] => 5
[post_date] => 2022-12-13 09:04:26
[post_date_gmt] => 2022-12-13 09:04:26
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 09:05:52
[post_modified_gmt] => 2022-12-13 09:05:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8192
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 8191
[post_author] => 5
[post_date] => 2022-12-12 16:19:19
[post_date_gmt] => 2022-12-12 16:19:19
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:55:07
[post_modified_gmt] => 2022-12-13 12:55:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8191
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 8190
[post_author] => 5
[post_date] => 2022-12-12 15:29:46
[post_date_gmt] => 2022-12-12 15:29:46
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-14 13:05:30
[post_modified_gmt] => 2022-12-14 13:05:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8190
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 8157
[post_author] => 5
[post_date] => 2022-12-12 15:23:50
[post_date_gmt] => 2022-12-12 15:23:50
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-28 14:06:57
[post_modified_gmt] => 2023-03-28 14:06:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8157
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 8152
[post_author] => 5
[post_date] => 2022-12-12 12:04:21
[post_date_gmt] => 2022-12-12 12:04:21
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:56:37
[post_modified_gmt] => 2022-12-13 12:56:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8152
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 8151
[post_author] => 5
[post_date] => 2022-12-12 11:56:08
[post_date_gmt] => 2022-12-12 11:56:08
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 13:04:22
[post_modified_gmt] => 2022-12-13 13:04:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 8150
[post_author] => 5
[post_date] => 2022-12-12 11:21:26
[post_date_gmt] => 2022-12-12 11:21:26
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-12 11:48:09
[post_modified_gmt] => 2022-12-12 11:48:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 8143
[post_author] => 5
[post_date] => 2022-12-12 11:10:19
[post_date_gmt] => 2022-12-12 11:10:19
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-12 11:10:19
[post_modified_gmt] => 2022-12-12 11:10:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8143
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 8142
[post_author] => 5
[post_date] => 2022-12-12 10:40:31
[post_date_gmt] => 2022-12-12 10:40:31
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:57:50
[post_modified_gmt] => 2022-12-13 12:57:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8142
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 8131
[post_author] => 5
[post_date] => 2022-12-12 09:57:36
[post_date_gmt] => 2022-12-12 09:57:36
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:49:55
[post_modified_gmt] => 2022-12-13 12:49:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 8130
[post_author] => 5
[post_date] => 2022-12-12 09:34:49
[post_date_gmt] => 2022-12-12 09:34:49
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:51:49
[post_modified_gmt] => 2022-12-13 12:51:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 8129
[post_author] => 5
[post_date] => 2022-12-12 08:55:53
[post_date_gmt] => 2022-12-12 08:55:53
[post_content] =>
[post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-13 12:45:31
[post_modified_gmt] => 2022-12-13 12:45:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 8051
[post_author] => 5
[post_date] => 2022-12-12 08:39:19
[post_date_gmt] => 2022-12-12 08:39:19
[post_content] =>
[post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:54:45
[post_modified_gmt] => 2023-01-10 13:54:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8051
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 5808
[post_author] => 5
[post_date] => 2022-10-04 10:04:03
[post_date_gmt] => 2022-10-04 10:04:03
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-04 10:04:03
[post_modified_gmt] => 2022-10-04 10:04:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 5782
[post_author] => 5
[post_date] => 2022-09-16 07:28:56
[post_date_gmt] => 2022-09-16 07:28:56
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:52:08
[post_modified_gmt] => 2023-01-10 13:52:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 5653
[post_author] => 5
[post_date] => 2022-08-25 12:56:30
[post_date_gmt] => 2022-08-25 12:56:30
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 12:24:08
[post_modified_gmt] => 2023-01-10 12:24:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5653
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 5652
[post_author] => 5
[post_date] => 2022-08-25 12:26:53
[post_date_gmt] => 2022-08-25 12:26:53
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:46:10
[post_modified_gmt] => 2023-01-10 11:46:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5652
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 5427
[post_author] => 5
[post_date] => 2022-07-22 15:20:29
[post_date_gmt] => 2022-07-22 15:20:29
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 13:37:17
[post_modified_gmt] => 2023-01-05 13:37:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5427
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 4661
[post_author] => 5
[post_date] => 2022-04-20 08:13:06
[post_date_gmt] => 2022-04-20 08:13:06
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:53:17
[post_modified_gmt] => 2022-10-03 13:53:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4661
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 4147
[post_author] => 5
[post_date] => 2022-04-18 12:53:51
[post_date_gmt] => 2022-04-18 12:53:51
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 16:24:43
[post_modified_gmt] => 2022-12-15 16:24:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 4148
[post_author] => 5
[post_date] => 2022-04-12 08:59:45
[post_date_gmt] => 2022-04-12 08:59:45
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-04 09:32:39
[post_modified_gmt] => 2022-10-04 09:32:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4148
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 4580
[post_author] => 5
[post_date] => 2022-03-31 14:34:38
[post_date_gmt] => 2022-03-31 14:34:38
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:02:54
[post_modified_gmt] => 2023-01-05 14:02:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4580
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 4223
[post_author] => 5
[post_date] => 2022-03-04 09:43:58
[post_date_gmt] => 2022-03-04 09:43:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 18:00:18
[post_modified_gmt] => 2022-05-31 18:00:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4223
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 4222
[post_author] => 5
[post_date] => 2022-03-04 09:14:41
[post_date_gmt] => 2022-03-04 09:14:41
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 11:13:06
[post_modified_gmt] => 2022-10-12 11:13:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4222
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 4221
[post_author] => 5
[post_date] => 2022-03-04 09:05:29
[post_date_gmt] => 2022-03-04 09:05:29
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:36:15
[post_modified_gmt] => 2022-09-26 14:36:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 4220
[post_author] => 5
[post_date] => 2022-03-04 08:47:04
[post_date_gmt] => 2022-03-04 08:47:04
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:08:10
[post_modified_gmt] => 2022-05-31 15:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 4219
[post_author] => 5
[post_date] => 2022-03-04 08:02:15
[post_date_gmt] => 2022-03-04 08:02:15
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-04 15:55:41
[post_modified_gmt] => 2023-01-04 15:55:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 4218
[post_author] => 5
[post_date] => 2022-03-03 14:17:53
[post_date_gmt] => 2022-03-03 14:17:53
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-04 15:10:14
[post_modified_gmt] => 2023-01-04 15:10:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 4217
[post_author] => 5
[post_date] => 2022-03-03 13:59:58
[post_date_gmt] => 2022-03-03 13:59:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:56:43
[post_modified_gmt] => 2022-05-31 17:56:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 4216
[post_author] => 5
[post_date] => 2022-03-03 13:45:21
[post_date_gmt] => 2022-03-03 13:45:21
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:56:00
[post_modified_gmt] => 2022-05-31 17:56:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 4215
[post_author] => 5
[post_date] => 2022-03-03 13:31:56
[post_date_gmt] => 2022-03-03 13:31:56
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 10:41:55
[post_modified_gmt] => 2022-09-29 10:41:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 4214
[post_author] => 5
[post_date] => 2022-03-03 12:54:33
[post_date_gmt] => 2022-03-03 12:54:33
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 16:33:50
[post_modified_gmt] => 2022-12-15 16:33:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 4213
[post_author] => 5
[post_date] => 2022-03-03 10:54:01
[post_date_gmt] => 2022-03-03 10:54:01
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:05:32
[post_modified_gmt] => 2022-05-31 15:05:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4213
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 4212
[post_author] => 5
[post_date] => 2022-03-02 14:54:16
[post_date_gmt] => 2022-03-02 14:54:16
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 12:56:25
[post_modified_gmt] => 2022-10-12 12:56:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4212
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 4210
[post_author] => 5
[post_date] => 2022-03-02 13:14:31
[post_date_gmt] => 2022-03-02 13:14:31
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:03:49
[post_modified_gmt] => 2022-07-13 12:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4210
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 4209
[post_author] => 5
[post_date] => 2022-03-02 12:07:13
[post_date_gmt] => 2022-03-02 12:07:13
[post_content] =>
[post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-13 13:16:54
[post_modified_gmt] => 2022-10-13 13:16:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4209
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 4205
[post_author] => 5
[post_date] => 2022-02-28 15:24:19
[post_date_gmt] => 2022-02-28 15:24:19
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 12:59:13
[post_modified_gmt] => 2022-10-12 12:59:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 4204
[post_author] => 5
[post_date] => 2022-02-28 14:53:11
[post_date_gmt] => 2022-02-28 14:53:11
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-14 13:07:32
[post_modified_gmt] => 2022-12-14 13:07:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 4201
[post_author] => 5
[post_date] => 2022-02-28 13:33:22
[post_date_gmt] => 2022-02-28 13:33:22
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:13:57
[post_modified_gmt] => 2023-01-10 13:13:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 4200
[post_author] => 5
[post_date] => 2022-02-28 13:13:29
[post_date_gmt] => 2022-02-28 13:13:29
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 11:13:52
[post_modified_gmt] => 2022-10-12 11:13:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 4161
[post_author] => 5
[post_date] => 2022-02-02 13:48:58
[post_date_gmt] => 2022-02-02 13:48:58
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 09:53:28
[post_modified_gmt] => 2022-12-15 09:53:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4161
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 4159
[post_author] => 5
[post_date] => 2022-02-02 13:10:48
[post_date_gmt] => 2022-02-02 13:10:48
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 11:15:11
[post_modified_gmt] => 2022-10-12 11:15:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 4158
[post_author] => 5
[post_date] => 2022-02-02 13:00:08
[post_date_gmt] => 2022-02-02 13:00:08
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-03 12:48:45
[post_modified_gmt] => 2023-01-03 12:48:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 4157
[post_author] => 5
[post_date] => 2022-02-02 12:54:56
[post_date_gmt] => 2022-02-02 12:54:56
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:13:37
[post_modified_gmt] => 2022-04-18 13:13:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4157
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 4156
[post_author] => 5
[post_date] => 2022-02-02 12:36:42
[post_date_gmt] => 2022-02-02 12:36:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-04 15:10:37
[post_modified_gmt] => 2023-01-04 15:10:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 4155
[post_author] => 5
[post_date] => 2022-02-02 12:19:16
[post_date_gmt] => 2022-02-02 12:19:16
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:26
[post_modified_gmt] => 2022-04-18 13:12:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 4154
[post_author] => 5
[post_date] => 2022-02-02 12:13:41
[post_date_gmt] => 2022-02-02 12:13:41
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-02 12:13:41
[post_modified_gmt] => 2022-02-02 12:13:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4154
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 4153
[post_author] => 5
[post_date] => 2022-02-02 12:10:13
[post_date_gmt] => 2022-02-02 12:10:13
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:28:28
[post_modified_gmt] => 2022-09-29 11:28:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4153
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 4152
[post_author] => 5
[post_date] => 2022-02-02 11:51:54
[post_date_gmt] => 2022-02-02 11:51:54
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:57:07
[post_modified_gmt] => 2022-09-26 14:57:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4152
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 4151
[post_author] => 5
[post_date] => 2022-02-02 11:39:24
[post_date_gmt] => 2022-02-02 11:39:24
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 13:00:22
[post_modified_gmt] => 2022-10-12 13:00:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 4150
[post_author] => 5
[post_date] => 2022-02-02 10:24:30
[post_date_gmt] => 2022-02-02 10:24:30
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:03
[post_modified_gmt] => 2022-04-18 13:01:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 4149
[post_author] => 5
[post_date] => 2022-02-02 10:15:42
[post_date_gmt] => 2022-02-02 10:15:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 16:35:19
[post_modified_gmt] => 2022-12-15 16:35:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4149
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 4146
[post_author] => 5
[post_date] => 2022-02-02 07:28:42
[post_date_gmt] => 2022-02-02 07:28:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-13 13:18:01
[post_modified_gmt] => 2022-10-13 13:18:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4146
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 4141
[post_author] => 5
[post_date] => 2022-01-31 14:31:23
[post_date_gmt] => 2022-01-31 14:31:23
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:40:20
[post_modified_gmt] => 2023-01-10 10:40:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 4140
[post_author] => 5
[post_date] => 2022-01-31 14:22:03
[post_date_gmt] => 2022-01-31 14:22:03
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:54:15
[post_modified_gmt] => 2023-01-10 10:54:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 4139
[post_author] => 5
[post_date] => 2022-01-31 14:18:32
[post_date_gmt] => 2022-01-31 14:18:32
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:58:00
[post_modified_gmt] => 2023-01-10 10:58:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 4138
[post_author] => 5
[post_date] => 2022-01-31 14:09:33
[post_date_gmt] => 2022-01-31 14:09:33
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:59:39
[post_modified_gmt] => 2023-01-10 10:59:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4138
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 4137
[post_author] => 5
[post_date] => 2022-01-31 13:53:37
[post_date_gmt] => 2022-01-31 13:53:37
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:02:20
[post_modified_gmt] => 2023-01-10 11:02:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 4136
[post_author] => 5
[post_date] => 2022-01-31 13:42:47
[post_date_gmt] => 2022-01-31 13:42:47
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:01:51
[post_modified_gmt] => 2023-01-10 11:01:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 4135
[post_author] => 5
[post_date] => 2022-01-31 13:25:08
[post_date_gmt] => 2022-01-31 13:25:08
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:59:11
[post_modified_gmt] => 2023-01-10 10:59:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 4134
[post_author] => 5
[post_date] => 2022-01-31 12:56:28
[post_date_gmt] => 2022-01-31 12:56:28
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:58:24
[post_modified_gmt] => 2023-01-10 10:58:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 4133
[post_author] => 5
[post_date] => 2022-01-31 12:22:56
[post_date_gmt] => 2022-01-31 12:22:56
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:56:11
[post_modified_gmt] => 2023-01-10 10:56:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4133
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 4131
[post_author] => 5
[post_date] => 2022-01-29 16:21:19
[post_date_gmt] => 2022-01-29 16:21:19
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:56:47
[post_modified_gmt] => 2023-01-10 10:56:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 4130
[post_author] => 5
[post_date] => 2022-01-29 15:34:50
[post_date_gmt] => 2022-01-29 15:34:50
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:57:20
[post_modified_gmt] => 2023-01-10 10:57:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 4129
[post_author] => 5
[post_date] => 2022-01-28 14:43:06
[post_date_gmt] => 2022-01-28 14:43:06
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 10:53:31
[post_modified_gmt] => 2023-01-10 10:53:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 4128
[post_author] => 5
[post_date] => 2022-01-28 13:38:44
[post_date_gmt] => 2022-01-28 13:38:44
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:07:15
[post_modified_gmt] => 2023-01-10 11:07:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 3812
[post_author] => 5
[post_date] => 2021-09-10 12:44:57
[post_date_gmt] => 2021-09-10 12:44:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:53:37
[post_modified_gmt] => 2022-10-03 13:53:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3812
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 3810
[post_author] => 5
[post_date] => 2021-09-10 12:21:33
[post_date_gmt] => 2021-09-10 12:21:33
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-12 11:25:05
[post_modified_gmt] => 2022-10-12 11:25:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3810
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 3809
[post_author] => 5
[post_date] => 2021-09-10 12:11:12
[post_date_gmt] => 2021-09-10 12:11:12
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:54:22
[post_modified_gmt] => 2022-10-03 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 3808
[post_author] => 5
[post_date] => 2021-09-10 11:59:11
[post_date_gmt] => 2021-09-10 11:59:11
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-16 08:32:00
[post_modified_gmt] => 2022-12-16 08:32:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 3807
[post_author] => 5
[post_date] => 2021-09-10 11:55:25
[post_date_gmt] => 2021-09-10 11:55:25
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-15 15:01:53
[post_modified_gmt] => 2022-12-15 15:01:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 3806
[post_author] => 5
[post_date] => 2021-09-10 11:47:18
[post_date_gmt] => 2021-09-10 11:47:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:55:26
[post_modified_gmt] => 2022-10-03 13:55:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 3805
[post_author] => 5
[post_date] => 2021-09-10 11:33:53
[post_date_gmt] => 2021-09-10 11:33:53
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-03 13:02:35
[post_modified_gmt] => 2023-01-03 13:02:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 3804
[post_author] => 5
[post_date] => 2021-09-10 11:20:59
[post_date_gmt] => 2021-09-10 11:20:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-21 12:59:30
[post_modified_gmt] => 2023-03-21 12:59:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 3803
[post_author] => 5
[post_date] => 2021-09-10 10:54:42
[post_date_gmt] => 2021-09-10 10:54:42
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:57:32
[post_modified_gmt] => 2022-10-03 13:57:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3803
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 3802
[post_author] => 5
[post_date] => 2021-09-10 10:45:57
[post_date_gmt] => 2021-09-10 10:45:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:58:08
[post_modified_gmt] => 2022-10-03 13:58:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 3801
[post_author] => 5
[post_date] => 2021-09-10 10:36:30
[post_date_gmt] => 2021-09-10 10:36:30
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-14 15:47:05
[post_modified_gmt] => 2022-12-14 15:47:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 3800
[post_author] => 5
[post_date] => 2021-09-10 10:25:59
[post_date_gmt] => 2021-09-10 10:25:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:58:45
[post_modified_gmt] => 2022-10-03 13:58:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 3799
[post_author] => 5
[post_date] => 2021-09-10 10:07:18
[post_date_gmt] => 2021-09-10 10:07:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-16 12:45:40
[post_modified_gmt] => 2022-12-16 12:45:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3799
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 3798
[post_author] => 5
[post_date] => 2021-09-10 10:02:07
[post_date_gmt] => 2021-09-10 10:02:07
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:59:19
[post_modified_gmt] => 2022-10-03 13:59:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 3797
[post_author] => 5
[post_date] => 2021-09-10 09:54:44
[post_date_gmt] => 2021-09-10 09:54:44
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-03 13:59:36
[post_modified_gmt] => 2022-10-03 13:59:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 3796
[post_author] => 5
[post_date] => 2021-09-10 09:03:43
[post_date_gmt] => 2021-09-10 09:03:43
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-11-09 15:00:19
[post_modified_gmt] => 2022-11-09 15:00:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 3757
[post_author] => 5
[post_date] => 2021-08-25 08:42:34
[post_date_gmt] => 2021-08-25 08:42:34
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:47:08
[post_modified_gmt] => 2023-01-11 15:47:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3757
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 3756
[post_author] => 5
[post_date] => 2021-08-25 08:10:37
[post_date_gmt] => 2021-08-25 08:10:37
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:39:31
[post_modified_gmt] => 2023-01-11 15:39:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3756
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 3755
[post_author] => 5
[post_date] => 2021-08-25 07:55:51
[post_date_gmt] => 2021-08-25 07:55:51
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:24:11
[post_modified_gmt] => 2023-01-19 09:24:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3755
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 3754
[post_author] => 5
[post_date] => 2021-08-24 13:43:37
[post_date_gmt] => 2021-08-24 13:43:37
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-12 13:59:38
[post_modified_gmt] => 2023-01-12 13:59:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3754
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 3753
[post_author] => 5
[post_date] => 2021-08-24 13:14:41
[post_date_gmt] => 2021-08-24 13:14:41
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 10:13:40
[post_modified_gmt] => 2023-01-19 10:13:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3753
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 3751
[post_author] => 5
[post_date] => 2021-08-24 12:54:56
[post_date_gmt] => 2021-08-24 12:54:56
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-12 13:20:29
[post_modified_gmt] => 2023-01-12 13:20:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3751
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 3749
[post_author] => 5
[post_date] => 2021-08-24 12:40:53
[post_date_gmt] => 2021-08-24 12:40:53
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-12 13:33:44
[post_modified_gmt] => 2023-01-12 13:33:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3749
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 3748
[post_author] => 5
[post_date] => 2021-08-24 12:31:07
[post_date_gmt] => 2021-08-24 12:31:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 14:17:38
[post_modified_gmt] => 2023-01-11 14:17:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 3747
[post_author] => 5
[post_date] => 2021-08-24 11:12:07
[post_date_gmt] => 2021-08-24 11:12:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:28:33
[post_modified_gmt] => 2023-01-11 15:28:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3747
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 3746
[post_author] => 5
[post_date] => 2021-08-24 10:45:05
[post_date_gmt] => 2021-08-24 10:45:05
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:55:51
[post_modified_gmt] => 2023-01-11 15:55:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3746
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 3744
[post_author] => 5
[post_date] => 2021-08-24 10:32:54
[post_date_gmt] => 2021-08-24 10:32:54
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-28 14:06:21
[post_modified_gmt] => 2023-03-28 14:06:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3744
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 3743
[post_author] => 5
[post_date] => 2021-08-24 10:19:00
[post_date_gmt] => 2021-08-24 10:19:00
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:53:13
[post_modified_gmt] => 2023-01-11 15:53:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3743
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 3736
[post_author] => 5
[post_date] => 2021-08-24 07:47:09
[post_date_gmt] => 2021-08-24 07:47:09
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-13 14:46:43
[post_modified_gmt] => 2023-01-13 14:46:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3736
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 3726
[post_author] => 5
[post_date] => 2021-08-23 16:13:39
[post_date_gmt] => 2021-08-23 16:13:39
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:23:48
[post_modified_gmt] => 2023-01-11 15:23:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3726
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 3725
[post_author] => 5
[post_date] => 2021-08-23 13:56:41
[post_date_gmt] => 2021-08-23 13:56:41
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:50:35
[post_modified_gmt] => 2023-01-11 15:50:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3725
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 3724
[post_author] => 5
[post_date] => 2021-08-23 13:11:07
[post_date_gmt] => 2021-08-23 13:11:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:27:12
[post_modified_gmt] => 2023-01-11 15:27:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3724
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 3722
[post_author] => 5
[post_date] => 2021-08-23 12:12:50
[post_date_gmt] => 2021-08-23 12:12:50
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-11 15:42:28
[post_modified_gmt] => 2023-01-11 15:42:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3722
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 3493
[post_author] => 5
[post_date] => 2021-08-10 11:15:39
[post_date_gmt] => 2021-08-10 11:15:39
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 14:19:31
[post_modified_gmt] => 2023-01-10 14:19:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3493
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 3344
[post_author] => 6
[post_date] => 2021-06-30 13:02:36
[post_date_gmt] => 2021-06-30 13:02:36
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-22
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 15:29:20
[post_modified_gmt] => 2023-01-05 15:29:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3344
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 3343
[post_author] => 6
[post_date] => 2021-06-30 12:57:07
[post_date_gmt] => 2021-06-30 12:57:07
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-21
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 15:31:21
[post_modified_gmt] => 2023-01-05 15:31:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3343
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 3342
[post_author] => 6
[post_date] => 2021-06-30 12:50:17
[post_date_gmt] => 2021-06-30 12:50:17
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 15:05:20
[post_modified_gmt] => 2023-01-05 15:05:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3342
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 3341
[post_author] => 6
[post_date] => 2021-06-30 12:44:43
[post_date_gmt] => 2021-06-30 12:44:43
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 15:04:39
[post_modified_gmt] => 2023-01-05 15:04:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3341
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 3339
[post_author] => 6
[post_date] => 2021-06-30 12:37:28
[post_date_gmt] => 2021-06-30 12:37:28
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-12 13:27:08
[post_modified_gmt] => 2023-01-12 13:27:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3339
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 3338
[post_author] => 6
[post_date] => 2021-06-30 12:27:08
[post_date_gmt] => 2021-06-30 12:27:08
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:23:29
[post_modified_gmt] => 2023-01-05 14:23:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3338
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 3336
[post_author] => 6
[post_date] => 2021-06-30 12:18:57
[post_date_gmt] => 2021-06-30 12:18:57
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:57:18
[post_modified_gmt] => 2023-01-05 14:57:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3336
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 3331
[post_author] => 6
[post_date] => 2021-06-30 12:09:31
[post_date_gmt] => 2021-06-30 12:09:31
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:55:43
[post_modified_gmt] => 2023-01-05 14:55:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3331
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 3329
[post_author] => 6
[post_date] => 2021-06-30 12:04:02
[post_date_gmt] => 2021-06-30 12:04:02
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-09 13:18:35
[post_modified_gmt] => 2023-01-09 13:18:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3329
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 3327
[post_author] => 6
[post_date] => 2021-06-30 11:47:34
[post_date_gmt] => 2021-06-30 11:47:34
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 13:58:59
[post_modified_gmt] => 2023-01-05 13:58:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3327
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 3326
[post_author] => 6
[post_date] => 2021-06-30 11:35:26
[post_date_gmt] => 2021-06-30 11:35:26
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-28 14:05:33
[post_modified_gmt] => 2023-03-28 14:05:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3326
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 3323
[post_author] => 6
[post_date] => 2021-06-30 11:15:16
[post_date_gmt] => 2021-06-30 11:15:16
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-09 13:12:53
[post_modified_gmt] => 2023-01-09 13:12:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3323
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 3321
[post_author] => 6
[post_date] => 2021-06-30 11:12:36
[post_date_gmt] => 2021-06-30 11:12:36
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-13-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:03:32
[post_modified_gmt] => 2023-01-05 14:03:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3321
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 3318
[post_author] => 6
[post_date] => 2021-06-30 10:46:25
[post_date_gmt] => 2021-06-30 10:46:25
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 09:20:27
[post_modified_gmt] => 2023-01-10 09:20:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3318
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 3316
[post_author] => 6
[post_date] => 2021-06-30 10:25:45
[post_date_gmt] => 2021-06-30 10:25:45
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-09 12:51:00
[post_modified_gmt] => 2023-01-09 12:51:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3316
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 3315
[post_author] => 6
[post_date] => 2021-06-30 10:19:01
[post_date_gmt] => 2021-06-30 10:19:01
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-05 14:19:23
[post_modified_gmt] => 2023-01-05 14:19:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3315
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 2909
[post_author] => 6
[post_date] => 2021-05-19 15:13:58
[post_date_gmt] => 2021-05-19 15:13:58
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:42:59
[post_modified_gmt] => 2023-01-10 13:42:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 2908
[post_author] => 6
[post_date] => 2021-05-19 15:08:05
[post_date_gmt] => 2021-05-19 15:08:05
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:40:09
[post_modified_gmt] => 2023-01-10 13:40:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 2907
[post_author] => 6
[post_date] => 2021-05-19 14:46:20
[post_date_gmt] => 2021-05-19 14:46:20
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 15:03:09
[post_modified_gmt] => 2022-08-12 15:03:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2907
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 2893
[post_author] => 6
[post_date] => 2021-05-19 14:40:45
[post_date_gmt] => 2021-05-19 14:40:45
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-28 14:17:46
[post_modified_gmt] => 2023-03-28 14:17:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[141] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 14:00:44
[post_modified_gmt] => 2023-01-10 14:00:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[142] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 11:14:51
[post_modified_gmt] => 2023-01-10 11:14:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[143] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 12:43:57
[post_modified_gmt] => 2023-01-10 12:43:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[144] => WP_Post Object
(
[ID] => 2885
[post_author] => 5
[post_date] => 2021-05-14 18:17:37
[post_date_gmt] => 2021-05-14 18:17:37
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-10 13:16:30
[post_modified_gmt] => 2023-01-10 13:16:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2885
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[145] => WP_Post Object
(
[ID] => 1221
[post_author] => 6
[post_date] => 2020-05-22 20:09:53
[post_date_gmt] => 2020-05-22 20:09:53
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfpi3-template-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:12:53
[post_modified_gmt] => 2023-01-17 17:12:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[146] => WP_Post Object
(
[ID] => 1205
[post_author] => 6
[post_date] => 2020-05-22 19:33:17
[post_date_gmt] => 2020-05-22 19:33:17
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 12:05:50
[post_modified_gmt] => 2023-01-19 12:05:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[147] => WP_Post Object
(
[ID] => 1204
[post_author] => 6
[post_date] => 2020-05-22 19:31:46
[post_date_gmt] => 2020-05-22 19:31:46
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-19 09:26:09
[post_modified_gmt] => 2023-01-19 09:26:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[148] => WP_Post Object
(
[ID] => 1203
[post_author] => 6
[post_date] => 2020-05-22 19:30:52
[post_date_gmt] => 2020-05-22 19:30:52
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-13 14:49:22
[post_modified_gmt] => 2023-01-13 14:49:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[149] => WP_Post Object
(
[ID] => 1202
[post_author] => 6
[post_date] => 2020-05-22 19:28:49
[post_date_gmt] => 2020-05-22 19:28:49
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-13 14:47:56
[post_modified_gmt] => 2023-01-13 14:47:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[150] => WP_Post Object
(
[ID] => 1159
[post_author] => 6
[post_date] => 2020-05-21 23:14:15
[post_date_gmt] => 2020-05-21 23:14:15
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:13:30
[post_modified_gmt] => 2023-01-17 17:13:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[151] => WP_Post Object
(
[ID] => 996
[post_author] => 7
[post_date] => 2020-05-18 19:58:18
[post_date_gmt] => 2020-05-18 19:58:18
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-01-17 17:16:23
[post_modified_gmt] => 2023-01-17 17:16:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[invalid_get] =>
[is_text_search] => 1
[has_agreement_filters] =>
[has_any_agreement_filter] => Array
(
)
[found_agreements] =>
[has_provision_filters] =>
[found_provisions] => 1
[lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
[lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
[lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
[lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
[lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
[lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
[lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
[issues_by_id:GHIAA2019\MapguideSearch:private] => Array
(
[101] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 29
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[100] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 28
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[66] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 9
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[53] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[84] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 65
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[271] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[72] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 49
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[281] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 34
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[46] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[278] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 51
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[80] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 65
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[257] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 55
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[109] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 37
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[48] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[50] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[88] => WP_Term Object
(
[term_id] => 88
[name] => License Grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 66
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[87] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 53
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[70] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 50
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[102] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 9
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[268] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 30
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[49] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[90] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 42
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[290] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 39
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[56] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 37
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[81] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 56
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[86] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 25
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[52] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[76] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 53
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[74] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 51
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[282] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 33
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
)
[issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
(
[equitable-access] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 29
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[pricing] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 28
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[benefit-revenue-sharing] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 9
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[business-model] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[confidentiality] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 65
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[donation] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[effect-of-termination] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 49
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[ensuring-continuity] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 34
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[access-to-medicines] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[roles-responsibilities] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 51
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[indemnity] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 65
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[information-sharing-information-sharing] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 55
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[insurance] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 37
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[ip-ownership] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[liability] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[license-grants] => WP_Term Object
(
[term_id] => 88
[name] => License Grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 66
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[ownership-ip] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 53
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[royalties-and-payments] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 50
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[outbreak-preparedness] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 9
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[supply-purchase-of-products] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 30
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[information-sharing] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[protection-results] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 42
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[publication-of-results] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 39
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[regulatory-strategy] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 37
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[warranties] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 56
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[technology-transfer] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 25
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[term-and-termination] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[term-of-agreement] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 53
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[termination-and-withdrawal] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 51
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[territory-access-commitments] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 33
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
)
[filter_issues:GHIAA2019\MapguideSearch:private] => Array
(
)
)
